Trial site
Sherbrooke
Sherbrooke, Quebec J1H 5N4, CanadaNot linked to an institution yet
- 13running trials
- 3closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 22 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 41 trial
- Status
- Recruiting7 trials
- Active, not recruiting6 trials
- Terminated2 trials
- Completed1 trial
- Lead sponsor
- Novartis Pharmaceuticals16 trials
Running trials
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071· Phase 1/2· Novartis Pharmaceuticals· Source
Recruiting
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
NCT07465653· Phase 1· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
NCT07282015· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922· Phase 4· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error